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Abstract
Background: Illumina’s Infinium SNP BeadChips are extensively used in both small and large-scale genetic studies.
A fundamental step in any analysis is the processing of raw allele A and allele B intensities from each SNP into
genotype calls (AA, AB, BB). Various algorithms which make use of different statistical models are available for this
task. We compare four methods (GenCall, Illuminus, GenoSNP and CRLMM) on data where the true genotypes are
known in advance and data from a recently published genome-wide association study.
Results: In general, differences in accuracy are relatively small between the methods evaluated, although CRLMM
and GenoSNP were found to consistently outperform GenCall. The performance of Illuminus is heavily dependent
on sample size, with lower no call rates and improved accuracy as the number of samples available increases. For
X chromosome SNPs, methods with sex-dependent models (Illuminus, CRLMM) perform better than methods
which ignore gender information (GenCall, GenoSNP). We observe that CRLMM and GenoSNP are more accurate at
calling SNPs with low minor allele frequency than GenCall or Illuminus. The sample quality metrics from each of
the four methods were found to have a high level of agreement at flagging samples with unusual signal
characteristics.
Conclusions: CRLMM, GenoSNP and GenCall can be applied with confidence in studies of any size, as their
performance was shown to be invariant to the number of samples available. Illuminus on the other hand requires
a larger number of samples to achieve comparable levels of accuracy and its use in smaller studies (50 or fewer
individuals) is not recommended.
Background
In the past decade, hundreds of studies investigating the
genetics of common human diseases have been pub-
lished [1]. High-density SNP microarrays cataloguing
variation identified in the HapMap project [2] have been
the enabling technology behind these large-scale gen-
ome-wide association studies. These microarrays allow
the collection of genotypes for many SNPs in many
individuals at relatively low cost. The two major produ-
cers of these microarrays are Affymetrix Inc. (Santa
Clara, CA) and Illumina Inc. (San Diego, CA). The plat-
forms offered by these companies differ substantially in
terms of array fabrication, probe design, sample prepara-
tion and hybridization protocol. However, both currently
genotype around 1 million SNPs per sample and also
include non-polymorphic probes for assessing copy
number variation in the genome.
Illumina’s BeadChips have rapidly increased in both
SNP density (from 100,000 to 1,000,000 SNPs) and in
the number of samples processed in parallel (1, 2, 4, 8
or 12 per BeadChip) over the past few years. Illumina
whole-genome SNP BeadChips use Infinium chemistry,
which differentially labels allele A and allele B with red
and green dye respectively [3,4]. A number of algo-
rithms are available for processing the raw signal from
these arrays into genotype calls. These methods include:
GenCall [5], Illumina’s proprietary method implemented
in the BeadStudio/GenomeStudio software; Illuminus
[6]; GenoSNP [7]; CRLMM [8-10]; Birdseed, available in
the Birdsuite software [11]; and BeagleCall [12].
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In this paper we compare the four widely applicable
methods GenCall, Illuminus, GenoSNP and CRLMM on
different data sets, measuring performance in terms of
accuracy and the ability of each method to flag poor
quality calls, SNPs and samples.
Methods
Algorithms
The four genotype calling methods we compare vary in
their modelling approaches and assumptions. Table 1
summarizes the major features of each algorithm in
terms of normalization method, underlying model and
computing platform supported. The main modelling dif-
ferences lie in the normalization method and clustering.
Normalization can occur either within sample (GenCall,
Illuminus, GenoSNP), or both within and between sam-
ples (CRLMM). Likewise, the model-based clustering
can occur within sample (GenoSNP) or between samples
(GenCall, Illuminus, CRLMM). In the description below,
we use Illumina’s nomenclature of X and Y to refer to
the intensities for the respective alleles (in general X =
allele A and Y = allele B).
GenCall is the standard vendor provided method from
Illumina [5] which is available as a module in the Bead-
Studio/GenomeStudio software. After reading in the
data from binary files (idats) produced by Illumina’s
scanning system, normalization using an affne transform
to rotate and re-scale the X and Y intensities is applied
to decrease dependence between the two alleles [4].
Normalization is performed separately for beads from
different ‘bead pools’. A ‘bead pool’ refers to a set of
beads that have been manufactured together and are
located in roughly the same physical position (strip) on
a BeadChip. Polar coordinates (R, θ) are calculated from
the normalized X and Y values. Clustering is performed
by the GenTrain algorithm, which is a between sample
model. Neural networks which take the polar coordinate
transformed data and estimate the SNP-specific
centroids for each genotype are used. Default cluster
centroids are calculated using data from a set of Hap-
Map samples [2] (Table 2). Alternatively, users may
perform clustering using the available samples to cali-
brate the cluster positions to the data. Genotypes are
then assigned by determining the nearest cluster. The
GenCall score (GC) is a confidence measure assigned to
each call which can be used to filter poor quality calls,
SNPs or samples. Illumina generally recommend that
calls with GC ≤ 0.15 represent failed genotypes. Aver-
aged GC scores over all SNPs from a given sample, or
across all samples for a given SNP can be used as sam-
ple or SNP quality metrics. A more commonly used
sample quality metric is the ‘no call rate’. For GenCall,
genotypes with GC score less than a given threshold
(0.15 in our analyses) are declared as missing. The pro-
portion of missing values, or ‘no calls’ in each sample
gives the no call rate; samples with higher rates are
deemed less reliable than samples with lower rates. No
call rates less than 1% should be expected for good
quality samples which have been properly processed
(Illumina Technical Support, personal communication).
A second alternative, named Illuminus [6], uses Gen-
Call normalized X and Y values as input. It models the
data from each SNP using a four component mixture
model which is fitted using an Expectation Maximiza-
tion (EM) algorithm to the strength (log(Xij + Yij)) and
contrast ((Xij - Yij)/(Xij + Yij)) values to summarize the
four possible states (AA, AB, BB or NC for no call). The
indices i and j refer to sample and SNP respectively.
Probabilities (pijk, where k = 1,....,4 is the genotype
index) indicating how likely a given call is correct under
the model are also available. The genotype with the
highest probability is the call reported to the user, and
the probability provides a call confidence measure. Illu-
minus fits a separate three component model for X
chromosome SNPs in male samples. A perturbation
score is also calculated to quantify how sensitive the
clustering is to changes in the initial values used in the
Table 1 Summary of the genotyping algorithms
compared
Method Major Features
Normalization Model System
GenCall W B Win
Illuminus W B Lin
GenoSNP W W Lin/Win
CRLMM W+B B Win/Lin/OSX
Key: W - within sample method; B - between sample method; Win - Windows
operating system; Lin - Linux operating system; OSX - Macintosh operating
system.
Table 2 Summary of the HapMap samples analyzed by
each algorithm
Chip type Training samples Test samples
550 k 112 (48:12:16:36) -
650 k 112 (48:12:16:36) 15 (0:0:0:15)
1 m 118 (49:13:17:39) 7 (3:0:0:4)
370 k Duo 115 (49:13:16:37) 45 (30:0:0:15)
1 m Duo 269 (89:45:45:90) 33 (11:3:2:17)
370 k Quad 225 (73:38:37:77) -
610 k Quad 225 (73:38:37:77) 27 (10:5:6:6)
660 k Quad 267 (88:44:45:90) 47 (30:0:0:17)
omni1 Quad 267 (88:44:45:90) 67 (29:4:4:30)
Total 1,710 241
The training samples were processed in-house by Illumina. The test samples
were processed by an independent core facility. The number of samples from
each of the four HapMap populations represented in each collection is given
in parentheses (CEU:CHB:JPT:YRI).
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EM-algorithm. This score serves as a SNP quality mea-
sure, and a cut-off of 0.95 and above, which equates to
95% or more of the calls agreeing after perturbation, is
recommended in the Illuminus documentation. Sample
quality can be measured by the percentage of calls with
a posterior probability less than a threshold (0.95 is
recommended). Alternatively the percentage of no calls
(NC or genotype index k = 4) obtained for each sample
can be used as a sample quality indicator. The Illuminus
software is implemented in C and is available from the
authors on request [6].
A third method, GenoSNP [7] is the only method
which ts a within-sample model to the data. GenoSNP
uses the raw (non-normalized) X and Y intensities from
GenCall, which are separated by bead pool and then
quantile normalized within sample. A four component
mixture model similar to Illuminus is then fitted to the
normalized log2(Xij + 1) and log2(Yij + 1) values. SNPs
from the same bead pool within a given sample are
called simultaneously using the model. This approach is
quite different to the other methods, which use between
sample information to fit the model. In GenoSNP, a
posterior probability is available for each call indicating
how likely the call comes from the class assigned. This
value serves as a call confidence measure. The average
posterior probability across all samples for a given SNP
may be used to filter SNPs, with lower average probabil-
ities indicative of SNPs with poorer clustering under the
model. A SNP cut-off of 0.95 or higher is recommended
for good quality data sets, and 0.8 or higher for lower
quality data sets. Likewise, the average posterior prob-
ability of all calls from a given sample can be used as a
sample quality metric. A sample quality threshold of 0.9
or higher is recommended. The GenoSNP software is
implemented in C and is available from the authors on
request [7].
The final method in our comparison, CRLMM, was
originally developed for Affymetrix data [8,9] and has
recently been adapted to suit Illumina’s Infinium SNP
BeadChips [10]. CRLMM extracts summarized X and Y
intensities directly from the idat files. For normalization,
SNPs are separated based on their physical location
(strip) on the BeadChip surface and simultaneously
quantile normalized between channels (X and Y) and
samples, using the reference distribution obtained from
the HapMap training samples (Table 2). Each strip con-
tains SNPs from multiple bead pools. After normaliza-
tion, SNP-specific log-ratios (Mij = log2 Xij - log2 Yij)
and average intensities (Sij = (log2 Xij + log2 Yij)/2) are
calculated for each array. To remove intensity depen-
dent effects of S on M, a three-component mixture
model with smoothing splines is fitted to each array via
the EM-algorithm. Next, a two-level hierarchical model,
with SNP-specific means and standard deviations
estimated from the relevant training data set using gen-
otype information from the HapMap project, is fitted.
The intensity-dependent splines and the SNP-specific
genotype means and standard deviations are combined
in the model [8,9]. In general, the model assumes 3
clusters, except for X chromosome SNPs in male sam-
ples, where a 2 cluster model is used. Genotype calls are
assigned by choosing the class that minimizes the nega-
tive log likelihood. CRLMM produces a number of qual-
ity assessment measures [9,13]. Per call confidence is
measured using the log-likelihood ratio test from the
hierarchical model. At the SNP level, the minimum dis-
tance between the heterozygote center and either of the
two homozygous centers provides a SNP confidence
score. A signal-to-noise ratio (SNR) for each sample
assesses the separation of the three major genotype clus-
ters within an array, with lower values indicative of
poorer quality data. The CRLMM method is implemen-
ted in R [14] and is available as part of the Bioconductor
project [15].
None of the methods compared make calls for the
non-polymorphic copy number specific probes which
are available on many Infinium chip types.
Data sets
Each of the four algorithms was applied to the data sets
described in the following sections.
HapMap data
We used data generated in-house at Illumina on Hap-
Map samples [2] from 9 different chip types. We refer
to these samples as training data sets, as they were used
by two of the algorithms (GenCall and CRLMM) to
train the respective models. HapMap data generated
independently by a different genotyping core facility,
were also analyzed. We refer to these samples as test
data sets, as they were run independently of the training
data used to calibrate two of the models. Any over-fit-
ting of the GenCall or CRLMM models to the training
data, which may give overly optimistic results for these
two methods on these data sets, should not be present
in the independent test samples. The number of samples
for each chip-type, with a break-down by HapMap
population is presented in Table 2. HapMap data has
the benefit of independent calls being available [16].
These calls can be used as the gold standard for com-
paring the accuracy of the various calling methods.
Association study data
Data from a recent genome-wide association study
(GWAS) on multiple sclerosis (MS) [17] were also used
in our comparison. Table 3 lists the number of samples
from each batch. Different batches correspond to the
various study centers in Australia and New Zealand
where the samples were collected from. Each sample
was analyzed using Illumina’s 370 k Duo BeadChip
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platform processed at the same core facility within a
6 month window [18]. A total of 1,943 samples were
genotyped using the four methods. We refer to this
study as the MS-GWAS in the remainder of this article.
Results and Discussion
Comparing accuracy using HapMap data
For each chip type, calls from the four methods were
compared with the independent genotypes available
from the HapMap project. Figure 1 shows the accuracy
of each algorithm for autosomal SNPs from three high
density chip types. The drop rate refers to the propor-
tion of SNPs which have been removed from the
accuracy calculation based on low call confidence mea-
sures. For most chip types, CRLMM gives slightly better
performance than GenoSNP and Illuminus. GenCall is
generally slightly worse than the other methods. Overall
differences between the four methods are small. Results
for other Infinium BeadChips are broadly similar (Addi-
tional File 1: Supplemental Figure S1). We repeated
these calculations on a per sample basis to obtain confi-
dence intervals (mean +/- 2 SE) for each method. Sup-
plemental Figure S2 in Additional File 1 shows the
results for the same 3 high density chip types shown in
Figure 1. In almost all instances, the confidence intervals
are non-overlapping which indicates that the small dif-
ferences observed between the methods are indeed
significant.
The performance of Illuminus is most variable among
the methods, sometimes producing near the best accu-
racy rates, while on other data sets it is the least accu-
rate. This phenomenon appeared to be related to
sample size. To investigate this more systematically,
660 k Quad training data were analyzed using Illuminus
with varying numbers of samples (from 5 to 100 in
increments of 5 samples). In Figure 2A, the decrease in
the number of ‘no calls’ as sample size increases is
shown. Accuracy also improves with increasing sample
number (Figure 2B). This analysis clearly demonstrates
that having more samples improves the performance of
Illuminus. Other methods aren’t adversely affected by
low numbers of samples, due to either the existence of a
training step (GenCall, CRLMM) which means model
parameters based on data from at least 100 samples are
available, or a within-sample approach (GenoSNP)
which leverages information from the many SNPs within
an array to estimate the necessary parameters and make
calls. Illuminus on the other hand only uses the data
available, so for small data sets the model parameters
will be less well estimated.
We also examined which method offers the best per-
formance on X chromosome SNPs (Figure 3), again
using accuracy with the independent HapMap project
calls as the gold standard. Calling algorithms which
apply different models to the male and female samples
(Illuminus and CRLMM) generally perform better than
methods which don’t (GenCall and GenoSNP). This
improvement comes from higher accuracy for male
samples. GenCall is generally slightly worse than the
other alternatives for X chromosome SNPs. As for the
autosomal SNPs, we see that the performance of Illumi-
nus is better when large numbers of samples are
available.
The accuracy versus drop rate calculations were
repeated using per SNP quality measures instead of indi-
vidual call confidence measures to filter entire SNPs
from the analysis (Additional File 1: Supplemental Fig-
ure S3). The Illuminus perturbation score for SNP qual-
ity gives very similar accuracy to CRLMM’s cluster
separation metric when large numbers of samples are
available (Additional File 1: Supplemental Figures S3A,
S3C and S3E), while the average per SNP posterior
probability of GenoSNP is slightly less accurate than
these methods. For smaller sample sizes, Illuminus does
less well. These measures are superior to GenCall’s aver-
age GC score.
Stratifying accuracy by minor allele frequency (MAF)
shows an interesting profile by method (Figure 4). For
both the 610 k Quad training and test data sets, both
GenoSNP and CRLMM have fairly consistent accuracies
across the range of minor allele frequencies (from 5% -
50%). GenCall and Illuminus have poorer performance
at lower minor allele frequencies, with increasing accu-
racy as frequency increases. These trends are consistent
as the number of low confidence calls removed
increases from 0% (Figure 4A and 4D) to 1% (Figure 4B
and 4E) and 2% (Figure 4C and 4F). Similar trends were
observed for other chip types (data not shown).
Higher-level performance assessment
The HapMap data sets analyzed are of very high quality
and not subject to the same sources of variation that
affect data from genome-wide association studies. In
large projects, the collection of samples and genotypes
may occur over a long period of time and arrays may be
Table 3 The number of samples analyzed from the
MS-GWAS
Sample batch Number of samples
1 647
2 346
3 338
4 133
5 75
6 404
Total 1,943
Each batch corresponds to a center where samples were recruited from.
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Figure 1 Accuracy versus drop rate plots for the four methods tested. Figures on the left-hand side show results for the training data sets
from 610 k Quad (A), 660 k Quad (C) and omni1 Quad (E) BeadChips. Figures on the right-hand side show results for the test data sets from the
610 k Quad (B), 660 k Quad (D) and omni1 Quad (F) BeadChips. Results are shown for autosomal SNPs only. CRLMM gives slightly more correct
calls than the other methods for these high density chip types. GenCall is almost always slightly worse than the other methods. GenoSNP
performs very consistently between data sets, achieving accuracy slightly below CRLMM. The accuracy of Illuminus seems to improve as the
number of samples available increases (accuracy starts off at around 0.992 in B with 27 samples, and increases to 0.995 in D with 47 samples
and 0.998 in A and C where in excess of 200 samples are available).
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Figure 2 The effect of sample size on results from Illuminus. Illuminus average no call rate for 660 k Quad training data for varying numbers
of samples (A). The average proportion of calls assigned to the ‘no call’ class by the model per sample declines as the number of samples
included in the analysis increases. Accuracy versus drop rate from 6 different Illuminus analyses in panel A involving varying numbers of samples
are also shown (B). As the number of samples analyzed increases, the accuracy measured in terms of agreement with the independent HapMap
calls improves. Note that SNPs assigned to the ‘no call’ class are excluded from these calculations.
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Figure 3 Accuracy versus drop rate plots for the four methods tested for X chromosome SNPs. Results are shown for all samples (A),
males only (B) or females only (C) from the 610 k Quad training data and all samples (D), males only (E) or females only (F) from the 610 k
Quad test data respectively. Methods with separate models for male and female samples (Illuminus and CRLMM) are generally more accurate
than methods which use the same model for both sexes (GenCall, GenoSNP). Performance of Illuminus in the test data set is worse than the
other three methods despite the sex-specific model. Again this is due to small sample size. In the training data set there were 121 males and
104 females, and in the test data set there were 13 males and 14 females.
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processed by multiple laboratories or core facilities. We
examine data from the MS-GWAS where samples have
been collected from different centers and processed in
batches (Table 3). GenCall, Illuminus and CRLMM were
each run independently on the different batches, while
GenoSNP was run one sample at-a-time. For GenCall,
re-clustering was carried out by the GenTrain algorithm
using the samples available instead of the default Hap-
Map cluster information. We use these data to assess
how well each method performs at flagging samples of
dubious quality.
Figure 5 shows why a metric for calling poor quality
samples is needed. For a typical sample, the raw signal
separates into 3 major clusters (Figure 5A), whereas for
a failed hybridization, distortions can be observed
(Figure 5B). Having a measure which can be used to
quickly flag poor quality arrays is essential in studies
involving large numbers of samples. For each method,
either a no call rate (GenCall, Illuminus), average pos-
terior probability (GenoSNP) or a signal-to-noise ratio
(CRLMM) can be calculated for each sample to assess
quality.
In Figure 6, the sample quality measures for the MS-
GWAS samples are shown for each method. Despite dif-
ferences in the measures used, the four methods flag
many of the same samples as potential outliers. Pairs
plots of the sample quality measures show this more
clearly (Additional File 1: Supplemental Figure S4). As a
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Figure 4 Accuracy by minor allele frequency. Accuracy for the 610 k Quad training data after 0% (A), 1% (B) and 2% (C) of calls with lowest
confidence were removed from the analysis. The x-axis in each plot shows MAF calculated from 0.05 (5%) to 0.5 (50%) in increments of 0.05
(5%). Similar plots are shown for the 610 k Quad test data, with figures D, E and F displaying accuracy after 0%, 1% and 2% of the calls with
lowest confidence were dropped from the analysis. Ignoring the overall differences in accuracy, which are consistent with the results seen in
Figure 1, we see that different methods vary in performance by MAF. For example, the accuracy profile of GenCall and Illuminus increases fairly
monotonically as the frequency of the rarer allele increases, with lowest accuracy obtained for SNPs with a MAF of 5% or lower. GenoSNP and
CRLMM are most accurate at calling rarer alleles, and have a more consistent accuracy profile as MAF varies. These trends are consistent as more
SNPs are excluded from the analysis. As we have seen in other analyses, the more samples available, the better the performance of Illuminus
with higher accuracy achieved on the training data (225 samples) compared to the test data (27 samples). In figures D, E and F, the accuracies
at minor allele frequencies of 5% and 10% are not plotted for Illuminus as they fall are below 0.994 (0.928 and 0.987 respectively at 0% drop
rate, 0.961 and 0.992 at 1% and 0.966 and 0.993 at 2%). For Illuminus and GenoSNP, SNPs assigned to the ‘no call’ class are excluded from the
accuracy calculations. These figures show results for autosomal SNPs only.
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summary, Figure 7 shows the degree of overlap between
the 20 worst ranking samples obtained using the respec-
tive sample quality metrics from each method. Visual
inspection of the data from many of these arrays indi-
cates unusual signal patterns (Additional File 1: Supple-
mental Figure S5), which makes them good candidates
to remove from further analysis.
The agreement between calls made on replicate sam-
ples was also assessed for each method. In Figure 8, the
agreement of calls between 10 replicate samples analyzed
from DNA extracted from blood and saliva from the MS-
GWAS are shown. High levels of agreement (> 98.5% of
calls) were obtained for all methods. The concordance
from one pair of samples (Figure 5) is not shown, due to
the poor quality of one of the replicate samples (Figure
5B - sample quality measures of 56.8%, 19.8% and 0.34
for GenCall, Illuminus and CRLMM respectively were
obtained for this sample, which are extreme values on
the respective scales shown in Figure 6). GenoSNP does
not produce calls for this sample. Presumably, the lack of
separation between the three clusters causes numerical
problems for the model.
The computing resources used to run each method on
a set of samples from the MS-GWAS were also exam-
ined. Table 4 shows the time taken and memory usage
of each algorithm. We note that GenCall was only
available under Windows, and was run on a different
computer to the other methods, which means our
results cannot be directly compared. In spite of this, we
can say that CRLMM is the fastest method of the three
which were run on the same linux system, followed clo-
sely by Illuminus and then GenoSNP. CRLMM is by far
the biggest consumer of RAM using approximately
three times as much memory as Illuminus. In contrast,
GenCall and GenoSNP use very little RAM.
Conclusions
Our study represents the largest comparison of genotyp-
ing methods for Illumina’s Infinium BeadChip platform
to date. We examined the performance on data sets
varying in size from tens to nearly 2000 samples from a
wide range of chip types.
Despite the differences in approach, the four methods
compared generally o er similar performance in terms of
accuracy with high quality HapMap data (> 99% agree-
ment), when call or SNP-specific quality scores were
used to filter data. CRLMM is marginally better than
GenoSNP and Illuminus (when sample size is large
enough), followed by GenCall. Each method also gives
high concordance between replicate samples (> 99% on
average). Variations in the ability of different methods
to correctly recover calls from SNPs with low minor
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Figure 5 Smoothed scatter plots of log-ratios versus average intensities for a sample run in replicate. This figure gives an example of
signal from a good quality array (A), with three well-separated clusters of points which approximately correspond to the AA (top cluster), AB
(middle cluster) and BB (bottom cluster) genotypes. Signal from the same sample which is clearly of very low quality is also shown (B). In this
plot we see one cluster of points, rather than the expected three. This major cluster occurs at low intensity (≈6), which is also highly unusual
(intensities between 8 and 14 on the log2-scale are typical). In each panel, non-normalized log-ratios (M) are plotted on the y-axis versus average
intensities (S) on the x-axis.
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allele frequency were observed, with CRLMM and Gen-
oSNP outperforming GenCall and Illuminus for SNPs
with the lowest MAF. This points to the benefit of bor-
rowing information between SNPs. In GenoSNP, this is
done explicitly by using the many observations from a
given bead pool to estimate parameters in the mixture
model and assign genotypes. For CRLMM, there will be
little information from the training data set on the het-
erozygous and homozygous cluster locations involving
the minor allele. However, since the SNP-specific para-
meters are updated by an empirical Bayes shrinkage
procedure, more weight will be placed on the priors in
these situations. These priors are derived from other
SNPs in the data set. Both approaches cope better than
methods which model the data from each SNP indepen-
dently (GenCall and Illuminus) when MAF is low. This
issue will be important as arrays include more rare var-
iants (MAF < 5%), such as SNPs discovered in the 1000
Genomes Project [19].
We observed that the performance of Illuminus
depends upon the number of samples available for the
analysis, with larger sample sizes (≥50), giving better
results in terms of no call rate and accuracy. For gen-
ome-wide association studies, low sample numbers are
not likely to be a problem, however for linkage studies,
which are often much smaller (< 10 samples), Illuminus
would not be the method of choice, unless the samples
can be analyzed within a larger batch of the same chip
type. All other methods can handle data from small-
scale projects without compromising performance.
We note that relative to the time expended recruiting
and collecting samples and processing arrays, the time
taken to run each algorithm is insignificant, with slightly
longer processing times unlikely to be a major factor
effecting the choice of method. The ability to parallelize
genotyping between multiple processors is a simple way to
reduce the time taken to process samples. All four algo-
rithms allow parallelization. By default, GenomeStudio
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Figure 6 Measures of sample quality for the MS-GWAS by genotyping method. Samples from different batches (from 1 to 6) are plotted in
different colors. For GenCall and Illuminus, the per sample no call rate (%) is used to measure sample quality. The GenoSNP per sample quality
measure is the average posterior probability of all calls within a sample, with higher values (closer to 1) indicative of higher quality. In CRLMM a
signal-to-noise score which measures separation between the 3 major clusters in each sample (Figure 5A) is calculated. For this measure, higher
scores represent higher quality. Despite the differences in scale, all methods appear to assign the most extreme quality scores (highest values in
the case of GenCall and Illuminus, and lowest for GenoSNP and CRLMM) to the same samples.
Ritchie et al. BMC Bioinformatics 2011, 12:68
http://www.biomedcentral.com/1471-2105/12/68
Page 9 of 12
divides the analysis between the available processors, split-
ting on sample or SNP depending upon the stage of the
analysis. For GenoSNP, which processes samples one-at-a-
time, parallelization is trivial; the user can easily divide the
samples between the processors available. For Illuminus
and CRLMM, the between-sample nature of the model-
ling, means that parallelization requires SNPs to be split
between processors. This feature is available as an option
in both algorithms. In CRLMM, the parallelization is
handled using the snow package in R.
As for timing, researchers involved in large scale stu-
dies are likely to have access to high performance com-
puting facilities, which means that large memory
requirements of methods like CRLMM, and to a lesser
extent Illuminus are not likely to pose a limitation. In
the most recent version of CRLMM, the memory foot-
print can be reduced through use of the ff package in R.
This package utilizes available disk space instead of
RAM when RAM is limited to store the raw data and
genotyping output.
One drawback of the current implementation of
CRLMM is its reliance on training data to calibrate the
model parameters, which means that for customized
genotyping, or genotyping in non-model organisms
(such as cow, pig and chicken), it cannot be applied due
to a lack of availability of HapMap-like training data.
We are currently investigating modifications to CRLMM
to ensure it can be applied in such settings. While Gen-
Call also includes a training step on HapMap data for
the chip types analyzed in this paper, it can also work in
an unsupervised manner, where it estimates cluster cen-
ters using the data available without the need for any
prior information. Illuminus and GenoSNP can also be
used on BeadChips containing customized human SNP
sets or SNPs from other diploid organisms.
Further work would be to extend the comparison to
include newer genotyping methods, such as BeagleCall
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Figure 7 Agreement between methods for the 20 lowest
quality samples ranked by each algorithm. All methods agree on
18 samples, GenCall, Illuminus and CRLMM all agree on a further
sample. CRLMM and Illuminus or GenoSNP and GenCall both agree
on another sample each. The sample flagged by GenoSNP alone was
ranked just outside the worst 20 samples by the other methods
(22nd, 23rd and 25th for GenCall, Illuminus and CRLMM respectively).
Plots of the raw signal from 3 samples ranked amongst the worst 20
by all methods are given in Additional File 1: Supplemental Figure S5.
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Figure 8 Concordance between genotype calls from replicate
samples by method. Boxplots of the replicate concordance for 10
samples from the MS-GWAS which were analyzed using DNA derived
from both saliva and blood. High concordance between replicates calls
(> 98.5% agreement) is the norm. The 8th sample is an exception, due to
poor quality of one of the replicates (Figure 5). For this pair of samples,
the concordance values are 16.6%, 15.6% and 40.8% for GenCall,
Illuminus and CRLMM respectively (values not plotted as they are off the
scale). GenoSNP did not produce calls for one of the samples (Figure 5B),
so concordance could not be calculated for this replicate pair.
Table 4 Summary of the computing resources required
by each method
Software Time taken (mins) Peak memory
usage (GB)
GenomeStudio (v 1.1.0)* 230 0.75
GenoSNP† 370⋄ 0.09
Illuminus† 38⋄ 12.2
CRLMM (v 1.2.4)† 28 38.2
These figures are based on the analysis of a set of 346 samples (batch 2) from
the MS-GWAS.
* run on a PC (Pentium quad core, 3 Ghz computer with 2 GB RAM) with file-
based storage enabled.
† run on a quad-core AMD Opteron 2.7 Ghz CPU linux machine with 64 GB
RAM.
⋄ timing does not include time taken by GenomeStudio to output X and Y
data used as input for these methods (30 mins and 0.65 GB RAM on the PC
we used).
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[12], which adds an extra layer of haplotype information
to the genotype calling process. The improvements
offered by the recently released update to the GenTrain
clustering algorithm (version 2) are also of interest. Gen-
Train2 was not used in this study, as output from this
software was unavailable for any of the data sets analyzed.
Since most studies published to date will be based on the
older version of GenCall, our comparison is still relevant.
Additional material
Additional file 1: Supplemental Figures.
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